DocGo shares fall after worse Q2 results, FY2026 sales guidance narrows
DocGo reports worse-than-expected Q2 financial results and narrows its FY2026 sales guidance, prompting shares to trade lower, per.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.